Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)

Garciaz, Sylvain; Decroocq, Justine; Bertoli, Sarah; Belhabri, Amine; Dumas, Pierre‐Yves; Simand, Célestine; Laribi, Kamel; Santagostino, Alberto; Carré, Martin; Schmidt, Aline; Requena, Gaspard Aspas; Himberlin, Chantal; Hospital, Marie‐Anne; Récher, Christian; Vey, Norbert

doi:10.1182/blood-2022-158247

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, for 12 patients who resumed VEN and/or AZA treatment, the rate of second remission was 50%. 69 In both the studies, the importance of evaluating MRD before ceasing therapy was emphasized.…”

Section: Prognostic Versus Predictive Biomarkers For Ven Use In Amlmentioning

confidence: 99%

“…In another study (n = 51), where half the patients had VEN +/− AZA ceased, the median treatment‐free remission observed was 10 months. Interestingly, for 12 patients who resumed VEN and/or AZA treatment, the rate of second remission was 50% 69 . In both the studies, the importance of evaluating MRD before ceasing therapy was emphasized.…”

Section: Prognostic Versus Predictive Biomarkers For Ven Use In Amlmentioning

confidence: 99%

See 1 more Smart Citation

BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond

Wei¹,

Roberts²

2023

HemaSphere

View full text Add to dashboard Cite

Altering the natural history of acute myeloid leukemia (AML) in unfit and older patients has proved a highly challenging hurdle, despite several decades of concerted clinical trial effort. The arrival of venetoclax (VEN) to the clinical stage represents the most important therapeutic advance to date for older patients with AML. In this review, we will explain how and why VEN works, summarize its remarkable pathway to regulatory approval, and highlight the key milestones that have been important for its successful development in AML. We also provide perspectives on some of the challenges associated with using VEN in the clinic, emerging knowledge regarding mechanisms of treatment failure, and current clinical research directions likely to shape how this drug and others in this new class of anticancer agents are used in the future.

show abstract

Section: Prognostic Versus Predictive Biomarkers For Ven Use In Amlmentioning

confidence: 99%

Section: Prognostic Versus Predictive Biomarkers For Ven Use In Amlmentioning

confidence: 99%